American Journal of Cardiology
Volume 105, Issue 5 , Pages 667-671 , 1 March 2010

Cardiovascular Event Rates in Diabetic and Nondiabetic Individuals With and Without Established Atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)

  • Michel Krempf, MD

      Affiliations

    • INSERM UMR915, l'Institut du thorax, Nantes et Université de Nantes, CHU, Nantes, France
    • Corresponding Author InformationCorresponding author: Tel: 33-2400-83073; fax: 33-2400-83079
    • ,
  • Klaus G. Parhofer, MD

      Affiliations

    • Department of Internal Medicine II, Klinikum Grosshadern, Ludwig-Maximilians University Munich, Munich, Germany
    • ,
  • Ph. Gabriel Steg, MD

      Affiliations

    • INSERM U-698, Université Paris 7, Centre Hospitalier Bichat-Claude, Bernard, Paris, France
    • ,
  • Deepak L. Bhatt, MD, MPH

      Affiliations

    • VA Boston Healthcare System and Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • E. Magnus Ohman, MD

      Affiliations

    • Duke Clinical Research, Institute and Duke University Medical Center, Durham, North Carolina
    • ,
  • Joachim Röther, MD

      Affiliations

    • Klinikum Minden, Hannover Medical School, Minden, Germany
    • ,
  • Shinya Goto, MD, PhD

      Affiliations

    • Department of Medicine, Tokai University School of Medicine, Kanagawa, Japan
    • ,
  • Blandine Pasquet, MSc

      Affiliations

    • Dèpartement d'Epidémiologie, Université Paris VII, Denis Diderot, Hôpital Bichat-Claude, Bernard, Paris, France
    • ,
  • Peter W.F. Wilson, MD

      Affiliations

    • Cardiology Division, Emory University School of Medicine, Atlanta, Georgia
    • ,
  • Reach Registry Investigators

Received 8 July 2009 ,Revised 13 October 2009 ,Accepted 13 October 2009.

References 

  1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234
  2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421
  3. Friedewald VE, Leiter LA, McGuire DK, Nesto RW, Roberts WC. The editor's roundtable: diabetes mellitus and coronary heart disease. Am J Cardiol. 2006;98:842–856
  4. Hu G, Jousilahti P, Qiao Q, Katoh S, Tuomilehto J. Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. Diabetologia. 2005;48:856–861
  5. Natarajan S, Liao Y, Sinha D, Cao G, McGee DL, Lipsitz SR. Sex differences in the effect of diabetes duration on coronary heart disease mortality. Arch Intern Med. 2005;165:430–435
  6. Lee CD, Folsom AR, Pankow JS, Brancati FL. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation. 2004;109:855–860
  7. Wu Y, Liu X, Li X, Li Y, Zhao L, Chen Z, et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults. Circulation. 2006;114:2217–2225
  8. Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Proteinuria and metabolic syndrome as predictors of cardiovascular death in non-diabetic and type 2 diabetic men and women. Diabetologia. 2006;49:56–65
  9. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52:1210–1214
  10. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006;29:1220–1226
  11. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary (The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)). Eur Heart J. 2007;28:88–136
  12. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180–189
  13. Steg PG, Bhatt DL, Wilson PW, D'Agostino R, Ohman EM, Rother J, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197–1206
  14. Tseng KH. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): response to Server, et al. Diabetes Care. 2005;28:2595–2596
  15. Norman PE, Davis WA, Bruce DG, Davis TM. Peripheral arterial disease and risk of cardiac death in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care. 2006;29:575–580
  16. Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation. 2008;117:1945–1954
  17. Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects. Diabetes Care. 2005;28:2901–2907
  18. Vaccaro O, Eberly LE, Neaton JD, Yang L, Riccardi G, Stamler J. Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial. Arch Intern Med. 2004;164:1438–1443
  19. Becker A, Bos G, de Vegt F, Kostense PJ, Dekker JM, Nijpels G, et al. Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease (10-Year follow-up of the Hoorn Study). Eur Heart J. 2003;24:1406–1413
  20. Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ. 2002;324:939–942

 The REACH Registry is sponsored by Sanofi-Aventis (Paris, France), Bristol-Myers Squibb (Paris, France), and the Waksman Foundation (Tokyo, Japan).

PII: S0002-9149(09)02591-0

doi: 10.1016/j.amjcard.2009.10.048

American Journal of Cardiology
Volume 105, Issue 5 , Pages 667-671 , 1 March 2010

Article Tools

* Image Usage & Resolution